CRSP
Crispr Therapeutics AG
NASDAQ: CRSP · HEALTHCARE · BIOTECHNOLOGY
$50.71
-2.59% today
Updated 2026-04-29
Market cap
$4.70B
P/E ratio
—
P/S ratio
1,340.31x
EPS (TTM)
$-6.47
Dividend yield
—
52W range
$33 – $78
Volume
2.0M
Crispr Therapeutics AG (CRSP) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $247000.00 | $5.16M | $41.00M | $3.12M | $289.59M | $719000.00 | $913.08M | $436000.00 | $370.00M | $35.00M | $3.51M |
| Revenue growth (YoY) | — | — | +1990.7% | +693.9% | -92.4% | +9169.8% | -99.8% | +126893.2% | -100.0% | +84762.4% | -90.5% | -90.0% |
| Cost of revenue | $1.51M | $12.57M | $42.24M | $69.80M | $113.77M | $179.36M | $269.41M | $101.18M | $110.25M | $130.25M | $110.25M | $232.96M |
| Gross profit | $-1.51M | $-12.33M | $-37.07M | $-28.80M | $3.12M | $289.59M | $-268.69M | $913.08M | $-109.81M | $239.75M | $-75.25M | $-229.45M |
| Gross margin | — | -4990.3% | -717.9% | -70.3% | 100.0% | 100.0% | -37369.7% | 100.0% | -25186.7% | 64.8% | -215.0% | -6537.0% |
| R&D | $1.51M | $12.57M | $42.24M | $69.80M | $113.77M | $179.36M | $221.38M | $438.63M | $461.64M | $387.33M | $320.65M | $265.33M |
| SG&A | $5.11M | $13.40M | $31.06M | $35.84M | $48.29M | $63.49M | $85.75M | $102.80M | $102.46M | $76.16M | $72.98M | $73.54M |
| Operating income | $-6.63M | $-25.73M | $-68.13M | $-64.65M | $-158.94M | $46.74M | $-354.44M | $373.53M | $-673.16M | $-222.54M | $-466.57M | $-568.32M |
| Operating margin | — | -10416.6% | -1319.3% | -157.7% | -5087.8% | 16.1% | -49295.5% | 40.9% | -154394.7% | -60.1% | -1333.0% | -16191.4% |
| EBITDA | $-6.59M | $-25.59M | $-13.67M | $-61.62M | $-155.42M | $51.47M | $-345.25M | $391.48M | $-648.99M | $-202.70M | $-447.31M | $-548.84M |
| EBITDA margin | — | -10358.7% | -264.7% | -150.3% | -4975.2% | 17.8% | -48018.2% | 42.9% | -148850.7% | -54.8% | -1278.0% | -15636.4% |
| EBIT | $-6.63M | $-25.71M | $-14.67M | $-64.65M | $-158.94M | $46.74M | $-354.44M | $373.53M | $-673.16M | $-222.54M | $-466.57M | $-568.32M |
| Interest expense | $0.00 | $108000.00 | $8.05M | $0.00 | $0.00 | $25.29M | $6.38M | $23.96M | $46.83M | — | — | — |
| Income tax | — | — | — | — | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-6.80M | $-25.83M | $-23.20M | $-68.36M | $-164.98M | $66.86M | $-348.87M | $377.66M | $-650.17M | $-153.61M | $-366.25M | $-581.60M |
| Net income growth (YoY) | — | -279.8% | +10.2% | -194.6% | -141.4% | +140.5% | -621.8% | +208.3% | -272.2% | +76.4% | -138.4% | -58.8% |
| Profit margin | — | -10456.7% | -449.3% | -166.7% | -5281.1% | 23.1% | -48520.9% | 41.4% | -149122.7% | -41.5% | -1046.4% | -16569.8% |